Caliway Biopharmaceuticals to Share Promising CBL-514 Study Results at IMCAS 2025 Conference in Paris
Caliway Biopharmaceuticals to Showcase Innovative CBL-514 Results at IMCAS 2025
Caliway Biopharmaceuticals is set to present significant findings from their CBL-0204 Phase 2b clinical trial at the upcoming IMCAS World Congress 2025, taking place in the heart of Paris. This event will highlight the advancements in aesthetic medicine and body contouring techniques that are reshaping the landscape of non-surgical fat reduction.
Scheduled for February 1, 2025, Dr. Michael H. Gold, an esteemed principal investigator for the clinical trials, will share the topline results pertinent to the efficacy of CBL-514, a pioneering injectable therapy aimed at large-area fat reduction. The exciting news reveals that over 80% of participants treated with CBL-514 experienced at least a one-grade improvement in the abdominal fat rating scale (AFRS).
CBL-514 stands out as a first-in-class drug, utilizing injectable lipolysis technology that efficiently reduces subcutaneous fat without adverse systemic effects. The trial's success paves the way for the impending Phase 3 global study, designed to further evaluate CBL-514’s effectiveness and safety.
Research Highlights
The results demonstrated from the CBL-0204 Phase 2b trial underscore an impressive efficacy and safety profile for CBL-514. Notably, this trial also adopted the FDA-recommended SCALE metrics, which are critical benchmarks for assessing new therapeutic options, further enhancing its credibility.
Study Details
- - Session Title: A novel non-surgical fat reduction treatment: A Phase 2b study investigating CBL-514 injection's efficacy in reducing abdomen subcutaneous fat
- - Date and Time: Saturday, February 1, 2025, at 3 PM (Central European Time)
- - Venue: Room 401 - Level 4, Palais des Congrès de Paris
The IMCAS World Congress is a prominent platform attracting over 18,700 healthcare and industry professionals each year, eager to learn about the latest trends and techniques in dermatology, plastic surgery, and aging science. Anchored at this congress, the speeches and sessions will provide critical insights into new methodologies aimed at non-surgical body contouring.
Future Directions
Caliway’s ambition for CBL-514 extends beyond mere fat reduction. Investigations are currently being conducted into its potential applications for various indications, including Dercum's disease and cellulite treatment. So far, clinical involvement from over 520 subjects has been documented across nine distinct studies, each reinforcing CBL-514's favorable safety profile while demonstrating precision in efficacy.
As the organization gears up for the pivotal Phase 3 trial slated for 2025, stakeholders and participants in the field can anticipate announcements that could revolutionize fat reduction treatments globally.
About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals is a pioneering biopharma company dedicated to the discovery of unique small-molecule therapies. Aiming to position itself as a leader in aesthetic medicine, the organization is publicly listed on the Taipei Exchange under the stock code TWSE-6919.
To find out more about the CBL-514 clinical trials, IMCAS event details, and upcoming product launches, visit Caliway's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.